WEBINAR: Oncogenic miRNAs via Alternative Splicing
In this webinar, David Corey, professor of pharmacology and biochemistry at UT Southwestern Medical Center, discusses his team’s work revealing a novel RNAi mechanism controlling gene expression through splicing in colon cancer models. Their work highlights miRNAs' importance in physiology and disease. The team leveraged a state-of-the-art bioinformatics platform that delivered insights in as little as two weeks and shows how democratizing bioinformatics with reproducible computation, interpretability, and user-friendliness accelerates discovery.
- Argonaute proteins' binding in human nuclear RNA and its effects on alternative splicing in colon cancer model systems.
- How to use RNAseq to analyze the effect of increasing cell density on gene expression and better understand human RNAi.
- Steps to identify a therapeutic target and develop a drug discovery program that might be able to successfully target a miRNA.
- How biologists with limited coding experience can overcome common challenges in contributing to large-scale data analysis.
Professor, Pharmacology & Biochemistry
UT Southwestern Medical Center
David Corey is a professor at UT Southwestern Medical Center and principal investigator for the Corey Lab. He received his undergraduate training in chemistry at Harvard University and his doctorate in chemistry at the University of California at Berkeley. He did postdoctoral work at the University of California at San Francisco before joining UT Southwestern in 1992. He currently serves as the president of the Oligonucleotide Therapeutics Society and is also executive editor for Nucleic Acids Research, which is responsible for handling 250 manuscripts per year. Corey's area of interest is the modulation of gene expression by synthetic nucleic acids.
Chief Scientific Officer and Co-Founder
Mark Kunitomi is the chief scientific officer and co-founder of Almaden Genomics. With over a decade of experience in research and development, he brings a wealth of knowledge and expertise to the company. Kunitomi received his doctorate from University of California, San Francisco. He focuses on the development of cutting-edge software and algorithms for the analysis and interpretation of bioinformatic data. He is a recognized leader in the field, with numerous publications and patents to his name. At Almaden Genomics, Kunitomi leads a team of highly skilled scientists and engineers, working to bring innovative solutions to the market and advancing the field of genomics.